Lexeo Therapeutics Reports Positive Interim Phase I/II Data for LX2020, Demonstrating Reduced Arrhythmia Burden in PKP2-ACM Patients

NEW YORK, NY — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC), as well as improvement in measures of right ventricular function and patient-reported symptoms. Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval. The final study design including the statistical analysis plan and confirmatory strategy remains subject to future discussions with the FDA.

“These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM. Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.”

“For families living with PKP2 arrhythmogenic cardiomyopathy, the risks and uncertainties reach far beyond the clinic and into every part of daily life,” said Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias (FIA). “Our community has waited a long time for treatments that might address the underlying cause of this disease. Early results like these give ACM families reason to hope for better, more targeted care. We look forward to larger studies that build on these findings.”

 

LX2020 Interim Update
Ten participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2×1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6×1013 vg/kg). As of the October 15, 2026 data cutoff date, nine of ten participants reached at least 12 months of follow-up, with the remaining participant reaching nine months of follow-up. Safety and efficacy data are summarized for all ten participants at latest assessment.

 

Clinical Data

  • 80% mean reduction in NSVT at latest assessment relative to baseline in high-dose cohorts (n=7), with deepening reduction in mean NSVT burden over time; six of seven participants demonstrated improvement at latest assessment
  • 44% mean reduction in PVC burden at latest assessment relative to baseline in high-dose cohorts (n=7); five of seven participants demonstrated improvement at latest assessment
  • Five of seven participants in high-dose cohorts reported symptom improvement at latest visit relative to baseline on the Patient Global Impression of Change (PGIC) scale, a patient-reported outcome measure
  • Preliminary evidence of stabilization or improvement in cardiac function assessed by cardiac MRI in the majority of participants in high-dose cohorts
  • Cardiac biopsy findings demonstrated dose-dependent increases in LX2020 transduction, mean exogenous PKP2 mRNA expression and mean PKP2 protein expression

Safety

  • LX2020 generally well tolerated across ten participants dosed
  • No clinically significant complement activation was observed and no participant discontinued the study
  • Previously disclosed elevations in liver function tests (LFT) were observed in the high-dose cohorts and were treated successfully per the trial protocol with no complications or hospitalizations
  • One previously disclosed Grade 3 serious adverse event of ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required

Regulatory Update and Next Steps

  • The FDA is open to use of guideline-defined NSVT as a primary surrogate endpoint in an accelerated approval pivotal study
  • Finalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027
  • Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027

 

Q3 2026 Earnings Update
Today, Lexeo also reported financial results for the third quarter of 2026:

  • Cash Position: As of September 30, 2026, cash, cash equivalents, and investments in marketable securities were $219.1 million, which Lexeo believes will be sufficient to fund operations into 2028
  • Research & Development Expenses: Research and Development expenses were $34.5 million for the three months ended September 30, 2026, compared to $15.7 million for the three months ended September 30, 2025. The majority of the increase was driven by one-time costs including the acquisition of Mantle Therapeutics, which closed in September 2026, as well as a development milestone that was achieved in the third quarter of 2026 related to LX2006 pivotal study initiation
  • General & Administrative Expenses: General and Administrative expenses were $5.9 million for the three months ended September 30, 2026, compared to $6.0 million for the three months ended September 30, 2025
  • Net Loss: Net loss was $38.3 million or $0.43 per share (basic and diluted) for the three months ended September 30, 2026, compared to $20.3 million or $0.33 per share (basic and diluted) for the three months ended September 30, 2025

Lexeo also announced the appointment of Toby Schilke as an independent director to the Board of Directors. Most recently, Mr. Schilke served as Chief Financial Officer of Crinetics Pharmaceuticals. He previously served as Chief Financial Officer at Revance Therapeutics and Achaogen. Earlier in his career, he held leadership roles across corporate development, commercial finance, marketing, and global operations at Roche and Genentech.

 

Corporate Webcast Details
Lexeo Therapeutics will host a webcast at 8:00 AM ET today, November 16, 2026. Analysts and investors can participate by accessing the webcast live on the Events & Presentations page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call.

 

About LX2020
LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion. LX2020 is being evaluated in the single-arm, open-label, multi-center HEROIC-PKP2 Phase I/II clinical trial (NCT06109181). LX2020 has been granted Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations by the FDA.

 

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.

 

Media Response
[email protected]

Investor Response
[email protected]